

GLAXOSMITHKLINE PLC  
Form 6-K  
April 20, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending April 2015

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

In accordance with DTR 3.1.4R(1)(a) and (c) GlaxoSmithKline plc ('GSK') was advised on 17 April 2015, of changes in the interests of the following Directors and Persons Discharging Managerial Responsibilities, following increases in interests in Ordinary Shares ('Shares'), at a price of 1611.45 pence per Share on 10 April 2015, following the re-investment of the dividend paid to shareholders on 9 April 2015.

Director/PDMR	Shares
Sir Andrew Witty	2063.469
Mr R G Connor	233.946
Mr S Dingemans	922.997
Mr S A Hussain	2111.840
Mr D S Redfern	801.120
Dr M M Slaoui	161.949
Ms C Thomas	983.411
Mr P C Thomson	336.617
Dr P J T Vallance	1192.237
Ms E Walmsley	924.677

Connected Person	Shares
Mrs K Thomson (connected person to Mr P C Thomson)	71.623

V A Whyte  
Company Secretary

20 April 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: April 20, 2015

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc